Immunic Therapeutics

🙏 Thank you, Multiple Sclerosis News Today and Lindsey Shapiro, for covering the positive outcome of the interim analysis of our phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis! 🔍 Dive deeper into the details here: ▶ https://bit.ly/4hg0LAS #ClinicalTrials #vidofludimus #IMU838 #ENSURE #MS #MultipleSclerosis #RMS #neuroprotection #Nurr1 #DHODH #Immunic #IMUX

🤝 We had a fantastic time at the Finance Day 2024 in Leipzig, Germany! Thank you, Karin Hofelich, GoingPublic Media AG and Plattform Life Sciences, for the invitation! The event was a wonderful opportunity to reconnect with colleagues and build new relationships. Our team onsite, Jessica Breu, VP Investor Relations & Communications, and Patrcia Remmele, Working Student Communications, truly enjoyed the experience. We are already looking forward to next year! ✨ #FinanceDay #LifeSciences #Immunic #IMUX #InvestorRelations #Networking

𝗙𝗶𝗻𝗮𝗻𝗰𝗲 𝗗𝗮𝘆 𝗟𝗲𝗶𝗽𝘇𝗶𝗴 𝟮𝟬𝟮𝟰 🤝 Connect with Jessica Breu, our VP Investor Relations and Communications, as she will be onsite at this event. The Finance Day is a cornerstone event for startups, growth companies, and capital market financing in life sciences sector. 🇩🇪 🗓️ When: October 24, 2024 📍 Where: Bio City Leipzig, Germany Join us as we connect with industry leaders and innovators! GoingPublic Media AG, Plattform Life Sciences #FinanceDay #LifeSciences #Immunic #IMUX #InvestorRelations #Networking

📢 ＮＥＷＳ📢 🎉 We are excited to announce the 𝗽𝗼𝘀𝗶𝘁𝗶𝘃𝗲 outcome of the interim analysis of our phase 3 ENSURE program of vidofludimus calcium in relapsing multiple sclerosis! An Independent Data Monitoring Committee (IDMC) reviewed unblinded data and confirmed that the predetermined futility criteria were not met. The IDMC has also recommended continuing the trial without changes, including no need for potential upsizing. The ENSURE program remains on track for completion in 2026. 🚀 ▶️ https://bit.ly/4dUGzld 🔍 Do you want to learn more? 🔗 Join our webcast today, 🗓️ at 8:00 am ET. Register here: https://bit.ly/48n36Gg. #ClinicalTrials #Vidofludimus #IMU838 #ENSURE #MS #MultipleSclerosis #RMS #Neuroprotection #Nurr1 #DHODH #Immunic #IMUX 

🤝 Immunic’s Specialist in Regulatory Operations & Systems, Silke Kropp, will be attending the Global Regulatory Affairs Summit 2024 taking place 🗓️ October 22-24 in Brussels, Belgium! 🇧🇪 🔍 This hybrid event offers comprehensive regulatory updates on Identification of Medicinal Products (IDMP), Regulatory Information Management (RIM), global e-submissions, legislation, and global markets. Whether you are attending in person or virtually, don’t miss the chance to connect with Silke! 📄 See you there!  #GPRAS Informa Connect Life Sciences #Biotech #RegulatoryAffairs #Immunic #IMUX

🌾 Imagine hardly ever being able to eat in a restaurant, because even a tiny breadcrumb could make you sick? 🍽️ 🔎 Our Chief Scientific Officer, Dr. Hella Kohlhof, explains the science behind IMU-856, an oral small molecule currently in clinical trials aimed at tackling celiac disease and other gastrointestinal conditions. Watch the Proactive video to discover how IMU-856 could transform the lives of patients with this uncureable autoimmune disease. 💙 🎥 https://bit.ly/3D5GaMZ #CeliacDisease #Celiac #Gastroenterology #gastrointestinal #Biotech #Immunic #IMUX #IMU856 #Proactive #WeLoveTheBeautyOfScience

❓ Is there an MS drug with a placebo-like safety profile? 🔎 Learn more about Immunic's small molecule, vidofludimus calcium, currently in phase 3 and 2 clinical trials for relapsing and progressive forms of multiple sclerosis, in this article by 📰 European Pharmaceutical Review ▶️ https://bit.ly/3XTRaH2 #MS #MultipleSclerosis #RMS #PMS #MSResearch #vidofludimus #Immunic #IMUX

🎗️ Do you want to learn more about the dual mode of action of vidofludimus calcium as a Nurr1 activator and DHODH inhibitor, and why we believe it has the potential to be broadly used in all forms of multiple sclerosis? 🎥 Tune in to the video by NeurologyLive recorded during this year's ECTRIMS congress with our Chief Medical Officer, Dr. Andreas Muehler, and Dr. Robert Fox from Cleveland Clinic, Ohio. ▶️ https://bit.ly/3TWIGhf They also discuss the interim results from our phase 2 CALLIPER trial, highlighting the consistent reduction of neurofilament light (NfL), giving vidofludimus calcium the potential to possibly slow disease progression in patients with progressive MS. 🧠 #MultipleSclerosis #MS #RMS #PMS #MSResearch #Vidofludimus #Nurr1 #Neuroprotection #DHODH #CALLIPER #NfL #neurofilament #ECTRIMS2024 #MSAwareness #Immunic #IMUX

✡️ Yom Kippur, the Day of Atonement, is a time for reflection, forgiveness, and renewal. At Immunic, we value the diverse beliefs and traditions that strengthen our global team. Wishing everyone honoring this day a meaningful and peaceful time. 🕊️ #YomKippur #Immunic #IMUX

🌍 On this World Mental Health Day, we want to shine a light on the mental health challenges faced by many living with multiple sclerosis (MS). As a company dedicated to finding new, clinically meaningful treatment options for MS, we understand that the disease not only affects the body but also takes a toll on mental well-being.   🎗️ Many patients struggle with depression, anxiety, or cognitive issues. Recognizing and addressing these challenges is key to building a support system that cares for a person’s overall well-being. 💛   Together, we can raise awareness and work towards a future where no one with MS has to face these battles alone.   #WorldMentalHealthDay #WMHD2024 #Awareness #MultipleSclerosis #MS #Immunic #IMUX